{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:04:23Z","timestamp":1778799863135,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Inflammatory bowel diseases (IBDs) are often associated with altered liver function tests (LFTs). There is little data on the relationship between abnormal LFT and IBD. Our study aimed to evaluate the prevalence and etiology of elevated LFT in patients with ulcerative colitis (UC) and to determine whether there is an association with clinical and demographic parameters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical records of the Gastroenterology Outpatients Clinic at a single center were reviewed and screened for patients with UC from 2005 to 2014. In total, 263 patients were included. Patients with Crohn\u2019s disease (CD), colitis indeterminate, and colitis of other origins were excluded. Abnormal LFT and liver injuries were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A cohort of 182 patients was analyzed (114 males, 68 females; mean age\u2009=\u200950.2 \u00b1 16.1 years). 58 patients had already been diagnosed with a hepatobiliary disorder. Patients with a known hepatobiliary disorder suffered from UC for a significantly longer duration. Elevated LFT in patients without known hepatobiliary disorders was 69.4%. Liver injury was found in 21.8%. A transient increase in abnormal LFT was shown in 59 patients (68.6%), a persistent increase was found in 27 patients (31.4%). Treatment with thiopurines was a risk factor for persistent elevated LFT (<jats:italic>p<\/jats:italic> =\u20090.029), steroids had a protective impact (<jats:italic>p<\/jats:italic> =\u20090.037).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study clearly highlights the importance of screening for hepatobiliary disorders and abnormal LFT in patients with UC, as the prevalence of hepatobiliary disorders and abnormal LFT is detected very often among this patient group.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1273797","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:19:35Z","timestamp":1704431975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Katharina","family":"Stratmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song\u00fcl","family":"Aydolmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Heling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Terjung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Vollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"CGast.S13125","DOI":"10.4137\/CGast.S13125","article-title":"Liver function test abnormalities in patients with inflammatory bowel diseases: a hospital-based survey","volume":"7","author":"Cappello","year":"2014","journal-title":"Clin Med Insights Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/ecco-jcc\/jjac013","article-title":"Drug-induced liver injury used in the treatment of inflammatory bowel disease","volume":"16","author":"N\u00fa\u00f1ez","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0002-9610(65)90018-8","article-title":"Sclerosing cholangitis. Review of recent case reports and associated diseases and four new cases","volume":"110","author":"Smith","year":"1965","journal-title":"Am J Surg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/MIB.0000000000000065","article-title":"Hepatobiliary manifestations of inflammatory bowel disease","volume":"20","author":"Yarur","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14740\/gr990w","article-title":"Hepatobiliary manifestations and complications in inflammatory bowel disease: a review","volume":"11","author":"Fousekis","year":"2018","journal-title":"Gastroenterol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.4254\/wjh.v13.i11.1534","article-title":"Liver involvement in inflammatory bowel disease: what should the clinician know?","volume":"13","author":"Losurdo","year":"2021","journal-title":"World J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis","volume":"9","author":"Ngu","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2036.2012.05063.x","article-title":"The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis","volume":"35","author":"Navaneethan","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/ibd.21219","article-title":"Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease","volume":"16","author":"Navaneethan","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MCG.0000000000000568","article-title":"Azathioprine and 6-Mercaptopurine-induced liver injury","volume":"51","author":"Bj\u00f6rnsson","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1025350","DOI":"10.3389\/fimmu.2022.1025350","article-title":"Vedolizumab for acute gastrointestinal graft-versus-host disease: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.4254\/wjh.v13.i12.1828","article-title":"Liver-side of inflammatory bowel diseases: hepatobiliary and drug-induced disorders","volume":"13","author":"Mazza","year":"2021","journal-title":"World J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/00365529709000186","article-title":"Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease","volume":"32","author":"Heikius","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/00365529850166275","article-title":"Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study","volume":"33","author":"Riegler","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"031","DOI":"10.1055\/s-2006-933561","article-title":"Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer","volume":"26","author":"Broom\u00e9","year":"2006","journal-title":"Semin Liver Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-2008-1040541","article-title":"Hepatobiliary complications of inflammatory bowel disease","volume":"8","author":"Schrumpf","year":"1988","journal-title":"Semin Liver Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/gut.35.1.84","article-title":"Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm","volume":"35","author":"Broom\u00e9","year":"1994","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4254\/wjh.v9.i13.613","article-title":"Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease","volume":"9","author":"Tran-Minh","year":"2017","journal-title":"World J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1365-2036.2005.02636.x","article-title":"Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease","volume":"22","author":"Bastida","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/flgastro-2018-101037","article-title":"Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease","volume":"10","author":"Yaccob","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated Oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/00365520410007971","article-title":"Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease","volume":"39","author":"Roseth","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis:correlation of the Rachmilewitz endoscopic activity index with fecal calpro- tectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity","volume":"20","author":"Lin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref33","author":"Schramm","year":"2017"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1273797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:19:48Z","timestamp":1704431988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1273797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":33,"alternative-id":["10.3389\/fmed.2023.1273797"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1273797","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"article-number":"1273797"}}